Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaccination Clear all
Completed Phase 3 Interventional Results available

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Vaccinations for Young Children (IVY)

NCT04203277
View directory record Official record
Conditions
Vaccination Refusal
Interventions
IVY
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Results available

Improving COVID-19 Vaccine Uptake Among Black and Latino Youth

NCT05293392
View directory record Official record
Conditions
COVID-19
Interventions
Culturally-Tailored COVID-19 Vaccine Uptake Intervention, Standard Care
Behavioral
Lead sponsor
Nemours Children's Health System
Other
Eligibility
Not listed
Enrollment
5,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 12, 2026, 2:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise

NCT07128095
View directory record Official record
Conditions
COVID-19, Sleep, Immunization; Infection, Physical Inactivity, Blood Pressure, Diet Habit, Mental Health Wellness 1
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 12, 2026, 2:54 PM EDT
Active, not recruiting Phase 2 Interventional

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00338377
View directory record Official record
Conditions
Melanoma
Interventions
Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Blood-Stage Plasmodium Vivax Cell Bank

NCT05095272
View directory record Official record
Conditions
Malaria
Interventions
HMPBS02-Pv
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 12, 2026, 2:54 PM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

NCT03531242
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 12, 2026, 2:54 PM EDT
Completed No phase listed Observational

Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population

NCT04963166
View directory record Official record
Conditions
Influenza Immunity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 4 Interventional

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

NCT02882100
View directory record Official record
Conditions
Influenza, Influenza-like Illness
Interventions
adjuvanted trivalent influenza vaccine, trivalent influenza vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 12, 2026, 2:54 PM EDT
Not listed Not applicable Interventional

Development Of a Virtual Stress Inoculation Training (SIT) Platform and Mobile Health App

NCT06494319
View directory record Official record
Conditions
PTSD, Trauma and Stressor Related Disorders, Traumatic Brain Injury
Interventions
Stress NAVIGATOR (Mobile Health Application), SIT NAVIGATOR
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination

NCT02145156
View directory record Official record
Conditions
HPV Vaccination Status
Interventions
Tailored educational materials, Untailored educational materials, Survey-only
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
1,294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 12, 2026, 2:54 PM EDT
Terminated Phase 2 Interventional

Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)

NCT00961376
View directory record Official record
Conditions
Melanoma
Interventions
PBMC re-infusion, CD25 depletion
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children

NCT01557621
View directory record Official record
Conditions
Immunization Rates
Interventions
Collaborative Pop-Based R/R: Phone/Mail Group, Collaborative Pop-Based R/R: Mail-Only Group, Practice-based Recall
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Months to 5 Years
Enrollment
68,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Results available

RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)

NCT05910879
View directory record Official record
Conditions
Health Behavior, Health Care Utilization, Vaccine Hesitancy
Interventions
Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Persuasiveness of Pro-inoculation Arguments

NCT05804825
View directory record Official record
Conditions
Vaccination Hesitancy, Human Papillomavirus Vaccination, Vaccine Refusal
Interventions
Argument inoculation messages, Simple forewarning message
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 12, 2026, 2:54 PM EDT
Active, not recruiting Phase 1 Interventional

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

NCT06006546
View directory record Official record
Conditions
Chronic HIV Infection
Interventions
426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Terminated Phase 1 Interventional Results available

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

NCT01810016
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 1 Interventional

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

NCT02010606
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging

NCT07132125
View directory record Official record
Conditions
HPV Vaccination Intent
Interventions
Default-style LLM chatbot, Conversational-style LLM chatbot, Public health informational materials
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana

NCT04939506
View directory record Official record
Conditions
Covid19, Vaccine Refusal, Vaccine Hesitancy
Interventions
COVID-19 Vaccine Education at the Point of COVID-19 Testing
Behavioral
Lead sponsor
Xavier University of Louisiana.
Other
Eligibility
18 Years to 99 Years
Enrollment
377 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 4 Interventional Results available

High Dose Influenza Vaccine in Nursing Home - Pilot Study

NCT01720277
View directory record Official record
Conditions
Influenza
Interventions
HD Fluzone Vaccine, SD Fluzone Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
2,957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 12, 2026, 2:54 PM EDT